Affordable Access

deepdyve-link
Publisher Website

High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up.

Authors
  • Mauclère-Denost, Sophie
  • Leboulleux, Sophie
  • Borget, Isabelle
  • Paci, Angelo
  • Young, Jacques
  • Al Ghuzlan, Abir
  • Deandreis, Desiree
  • Drouard, Laurence
  • Tabarin, Antoine
  • Chanson, Philippe
  • Schlumberger, Martin
  • Baudin, Eric
Type
Published Article
Journal
European Journal of Endocrinology
Publisher
Bioscientifica
Publication Date
Feb 01, 2012
Volume
166
Issue
2
Pages
261–268
Identifiers
DOI: 10.1530/EJE-11-0557
PMID: 22048971
Source
Medline
License
Unknown

Abstract

Employing a high-dose strategy at the time of mitotane initiation enabled therapeutic plasma levels of mitotane to be reached within 1 month in 27% of the total group of patients. If this strategy is adopted, we suggest that mitotane dose is readjusted according to plasma mitotane levels at 1 or/and 2 months and patient tolerance.

Report this publication

Statistics

Seen <100 times